The new drug nalbuphine, which acts on opioid receptors, has been shown to be effective in reducing chronic cough in patients with idiopathic pulmonary fibrosis (IPF). The results come from a phase IIb clinical trial called CORAL. Nalbuphine extended-release (ER) reduces objective cough, which is one of the main symptoms of IPF. This is a new therapeutic option, since chronic cough significantly worsens the quality of life of patients with this serious lung disease. The study confirmed the potential of this drug approach as an adjunctive treatment to existing antifibrotic drugs such as pirfenidone and nintedanib, which slow the progression of fibrosis. Nalbuphine represents a promising way to alleviate the symptoms of IPF and improve the well-being of patients.